Company Profile
Vetter
3.0
Avg Sentiment
Sentiment Over Time
Analysis Timeline
3.0
Score
2026-01-24
"Leading private fill-and-finish provider, positioned to benefit from increased demand for injectable biologics, including GLP-1s."